BBC Report on alzheimer drug donanemab seen as turning point in dementia fight

A big development made in the fight against Alzheimer’s disease. BBC reported that a new drug is being seen as a turning point in the battle against Alzheimer’s disease as the global trial confirmed the new drug slows cognitive decline. What is the name of the drug that slows cognitive decline in the fight against Alzheimer’s? The drug that has suddenly become the hope of light in the dark is called “Donanemab”. Donanemab is the name of the new drug that is being hailed as a turning point. If you are scrambling to the internet to know what is Donanemab and how it treats Alzheimer’s disease, the following sections of this article will help you in knowing this. Just stick with this page and go through it till the end. Scroll down the page and take a look below.

BBC Report on alzheimer drug

Reports have suggested that antibodies developed because of Donanemab help in the early stages of Alzheimer’s disease as it clears a protein that builds up in the brain of people with this type of dementia. Although Donanemab is not a cure for Alzheimer’s disease. According to the charities, the results in the Journal JAMA mark a new era where the disease can be cured. However, the drug watchdog of the United Kingdom has begun assessing it for possible NHS use. This drug, Donanemab, reportedly only works in Alzheimer’s, not in other types of dementia. Among other types of dementia, one is vascular dementia. Swipe down the page and read more details.

The results of the global trials suggested that the new drug Donanemab appears to slow down the pace of the disease by one-third and let people keep more of their daily live tasks and activities such as making food and doing their hobbies. An 80-year-old man from the UK named Mike Colley who is one of a few dozen patients, took part in the global trial. Recently, he spoke up with BBC. Continue reading this article and know what Mike Colley said.

Mike believes he is one of the luckiest people you will ever meet, he gets an infusion every month at a hospital in London. Mike was having problems with memory and could not make decisions just before he started the trial. Mike’s son Mark said, “Seeing him struggle with processing information and solving problems was very hard. But I think the decline is reaching a plateau now.”. Now Mike feels more confident every day.